Pneumonia

NasVax Finalizes Share Purchase Agreement with Protea Vaccine Technologies

Published in Vaccine Weekly, December 10th, 2008

NasVax Ltd. (TASE: NSVX), an Israeli company developing a technology for improving vaccines and immunotherapeutics, announces that it has signed an agreement with Protea Vaccine Technologies Ltd (Protea) to purchase all of the company's shares.

Protea is developing an innovative next-generation vaccine against diseases caused by Streptococcus pneumoniae, based on widely conserved pneumococcal proteins. Pneumococcal vaccine is one of the two largest market segments in prophylactic vaccines. Sales of $2.5B for pneumococcal vaccines in 2007 are growing at an annual rate of >30%.

Zvika Rubenstein, CEO of the Meytav Technological Incubator (Meytav),...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2008-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry